Achievements and Publications

Achievements

I. Discovery of driver gene fusions in solid tumors

A major part of our publications focuses on discovery and characterization of recurrent gene fusions in breast cancer and solid tumors, and the integrative bioinformatic approach to discover them from multidimensional genomic datasets. We also pioneered a universal concept signature (ConSig) analysis that employs molecular concept fingerprints for high-throughput interpretation of the biological function of genetic aberrations underlying cancer. Our studies have led to the discovery of the first oncogenic KRAS rearrangements in a rare subset of metastatic prostate cancers, and recurrent NFE2 rearrangements in lung adenocarcinoma. 

1. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nature Biotechnology. 2009 27:1005-1011. Read More.

2. Wang XS*, Shankar S*, Dhanasekaran SM*, Ateeq B, Prensner JR, Yocum AK, Pflueger D, Jing X, Fries DF, Han B, Li Yong, Cao Q, Cao X, Maher CA, Kumar SC, Demichelis F, Tewari AK, Kuefer R, Omenn GS, Palanisamy S, Rubin MA, Varambally S, Chinnaiyan AM. Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. Cancer Discovery. 2011 1:35-43. Read More.

II. Characterization of pathological recurrent gene fusions in more aggressive and therapy resistant breast cancer

Our key achievements in breast cancer genetics lie in the discoveries of two recurrent gene fusions in major breast cancer entities. First, we identified an ESR1-CCDC170 fusion that endows more aggressive phenotypes and endocrine resistance in a significant subset of luminal breast cancers. ESR1-CCDC170 remains the most important gene fusion yet reported in luminal breast cancer, and its clinical significance in endocrine resistance and tumor relapse has been supported by multiple following clinical studies. Our recent studies suggest a potential therapeutic strategy to target this fusion via HER2/SRC inhibitors. Second, through analysis of WGS datasets, we identified a novel BCL2L14-ETV6 fusion that is specific to triple-negative breast cancer (TNBC). This fusion is preferentially detected in more aggressive TNBC forms, and promotes epithelial mesenchymal transition and paclitaxel resistance. To date, this is the first 3’ ETV6 fusion yet reported in solid tumors. Furthermore, we also identified a novel non-traditional RAD51AP1-DYRK4 chimera underpinning the metastasis-prone behaviors of more aggressive breast cancer forms. By conferring selective vulnerability to MEK inhibitors, RAD51AP1-DYRK4 may be an Achilles heel of these deadly tumors that otherwise could have a devastating clinical outcome.

1.   Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJN, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS#. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers. Nature Communications. 2014 5:4577. Read More.

2.   Lee S*, Hu Y*, Loo SK, Tan Y, Bhargava R, Lewis MT, Wang XS#. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer. Proc Natl Acad Sci U S A. 2020 18:9912-9921. Read More.

3.   Li Li, Ling Lin, Jamunarani Veeraraghavan, Yiheng Hu, Xian Wang, Sanghoon Lee, Ying Tan, Rachel Schiff, Xiao-Song Wang#. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Research. 2020 22:84. Read More.

In addition to gene fusions, we also identified a novel non-traditional RAD51AP1-DYRK4 chimera underpinning the metastasis-prone behaviors of more aggressive breast cancer forms that lack well-defined targets for effective intervention. By conferring selective vulnerability to MEK inhibitors, RAD51AP1-DYRK4 may be an Achilles heel of these deadly tumors that otherwise could have a devastating clinical outcome. 

4.  Liu CC*, Veeraraghavan J*, Tan Y, Kim JA, Wang X, Loo SK, Lee S, Hu Y, and Wang XS#. A novel neoplastic fusion transcript, RAD51AP1-DYRK4, confers sensitivity to the MEK inhibitor trametinib in aggressive breast cancers. Clinical Cancer Research. 2021 3:785-798. Read More.

5. Loo SK, Yates ME, Yang S, Oesterreich S, Lee AV, Wang XS#. Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance. Genes Chromosomes Cancer. 2022 61(5):261-273. Read More.

III. Identification of actionable kinase target in more aggressive luminal breast cancers

Another research focus of our lab is to identify actionable kinase targets in aggressive breast cancers. First, we identified TLK2 as a key kinase target that is frequently amplified in aggressive luminal breast cancers. TLK2 promotes breast cancer invasiveness, modulates G1/S cell cycle transition, impairs G2/M checkpoint, and predicts worse clinical outcome. This study represents the first comprehensive analysis of TLK2 function in aggressive luminal breast cancers. Second, we identified a serine-threonine kinase target NLK and revealed its key role in breast cancer endocrine resistance. We then went on to identify a dual p38 and NLK inhibitor and evaluated its therapeutic value in preclinical models of de novo and acquired endocrine-resistant cancers. Furthermore, we also identified another kinase target MAP3K3 that endow breast carcinogenesis and resistance to cytotoxic chemotherapy.

1.  Wang X, Veeraraghavan J, Liu C, Cao X, Qin L, Kim J, Tan Y, Loo S, … Mitchell T, Li S, Ellis M, Hilsenbeck SG, Schiff R, Wang XS#. Therapeutic targeting of nemo-like kinase in primary and acquired endocrine-resistant breast cancer. Clinical Cancer Research. 2021 Feb 4.  Read More.

2.  Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R. and Wang XS#. Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nature Communications. 2016 7:12991. Read More.

3.  Kim JA, Anurag M, Veeraraghavan J, Schiff R, Li K, Wang XS#. Amplification of TLK2 Induces Genomic Instability via Impairing the G2/M Checkpoint. Mol Cancer Res. 2016 14:920-927. Read More.

4.   Fan Y*, Ge N*, Wang XS*, Sun W*, Mao R, Bu W, Creighton CJ, Zheng P, Vasudevan S, An L, Yang J, Zhao YJ, Zhang H, Li XN, Rao PH, Leung E, Lu YJ, Gray JW, Schiff R, Hilsenbeck SG, Osborne CK, Yang J, Zhang H. Amplification and overexpression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. The Journal of Pathology. 2014 232:75-86. Read More.

IV. iGenSig initiatives for precision oncology based on genome-wide sequencing

Our achievements in genomics based precision oncology focus on developing a new class of transparent and interpretable computational methods called integral genomic signature (iGenSig) analyses, that address the challenges of cross-dataset modeling through leveraging information redundancies within high-dimensional genomic features, averaging feature weights to prevent overweighing, and extracting unbiased genomic information from large tumor cohorts. Our iGenSig precision medicine initiatives aim to build a computational framework to facilitate tailored cancer therapy based on multi-omics data. Furthermore, we developed a Concept Signature Enrichment Analysis (CSEA) for deep functional assessment of the pathways enriched in a genomic signature based on the framework of shared concept signatures between gene sets at multiple functional levels. Grounded on this method we further developed an Indepth-Pathway package specialized for pathway discovery from single-cell sequencing data.

1.       Wang XS#, Lee S, Zhang H, Tang G, Wang Y. An integral genomic signature approach for tailored cancer therapy using genome-wide sequencing data. Nature Communications. 2022 13(1):2936.  Read More.

2.       Xu Chi, Maureen A. Sartor, Sanghoon Lee, Meenakshi Anurag, Snehal Patil, Pelle Hall, Matthew Wexler, Xiaosong Wang#. Universal Concept Signature Analysis: Genome-Wide Quantification of New Biological and Pathological Functions of Genes and Pathways. Briefings in Bioinformatics, Oct. bbz093. Read More.

3.       Lee S, Deng L, Wang Y, Wang K, Sartor MA, Wang XS#. IndepthPathway: an integrated tool for in-depth pathway enrichment analysis based on single-cell sequencing data. Bioinformatics. 2023 Jun 1;39(6): btad325 Read More.

V. Computational Immunogenomics and genome-wide discovery of tumor antigen targets and predictive biomarkers for cancer immunotherapy

Another major area of our publications focuses on computational immunogenomics aimed at identifying tumor specific antigen targets and predictive biomarkers for cancer immunotherapy. As our signature study, we developed an integrated computational-experimental approach called HEPA-PARSE for genome-wide detection of clinically important tumor-specific antigen targets for cancer immunotherapy (Cancer Research 2012). Furthermore, we recently discovered a novel genetic biomarker called intragenic rearrangement burden that dictates T-cell infiltration and predict immunotherapy response in TMB-low cancer types such as breast, ovarian, esophageal, and endometrial cancers (Cancer Immunology Research, accepted). We also built a public database called HPTAA that hosts putative tumor associated antigens cataloged based on gene expression data. 

1.       Zhang H, Lee S, Muthakana R, Lu B, Boone DN, Lee D, Wang XS#. Associations of intragenic rearrangement burden with immune cell infiltration and response to immune checkpoint blockade in cancer. Cancer Immunology Research. 2024. Feb. OF0-9 Read More.

2.       Xu QW, Zhao W, Wang Y, Sartor MA, Han DM, Deng JX, Ponnala R, Yang JY, Zhang QY, Liao GQ, Qu YM, Li L, Liu FF, Zhao HM, Yin YH, Chen WF, Zhang Y#, Wang XS#. An integrated genome-wide approach to discover tumor specific antigens as potential immunological and clinical targets in cancer. Cancer Research. 2012 72:6351-61. Read More.

3.       Wang XS*, Zhao H*, Xu Q, Jin W, Liu C, Zhang H, Huang Z, Zhang X, Zhang Y, Xin D, Simpson AJ, Old LJ, Na Y, Zhao Y, Chen W. HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma. Nucleic Acids Research. 2006 34: D607-12.  Read More.

VI. Identification of novel urine biomarkers for urothelial carcinoma and discovery of the UCA1 gene, one of the most studied lncRNA in cancer.

Our achievements in urological oncology lie in identification of two urine biomarkers UCA1 and UPK3A for sensitive and specific detection of bladder cancers. Among these, UCA1 is one of the most commonly studied long non-coding RNA (lncRNA) first cloned and named by Dr. Wang (Clinical Cancer Research. 2006). This long non-coding RNA was later found to be a key oncogene in the tumorigenesis of multiple cancer types and has been widely studied worldwide (a search of google scholar resulted in 13800 publications). As suggested by recent reviews, UCA1 has become one of the most reported urinary biomarker, and a meta-analysis of seven studies showed that UCA1 has a sensitivity of 84% and specificity of 87% for detecting bladder cancer (Medicine 100:e24805, 2021).

1.       Wang XS*, Zhang Z*, Wang HC, Cai JL, Xu QW, Li MQ, Chen YC, Qian XP, Lu TJ, Yu LZ, Zhang Y, Xin DQ, Na YQ, Chen WF. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clinical Cancer Research. 2006 12:4851-8. Read More.

2.       Lai YQ, Ye JX, Chen J, Zhang LB, Wasi LJ, He ZS, Zhou LQ, …Gui YT, Cai ZM, Wang XS#, Guan ZC#. UPK3A：A Promising Novel Urinary Marker for the Detection of Bladder Cancer. Urology. 2010 76:51. Read more.

VII. Discovery of epigenetic targets in breast cancer

Furthermore, our lab also identified several other key breast cancer targets. First, we identified an epigenetic-activated oncogene HORMAD1 that is preferentially expressed in basal-like breast cancer, and our lab has studied its role in rucaparib sensitivity using preclinical mouse models. We also discovered MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.

1.       Wang X, Tan Y, Cao X, Kim JA, Chen T, Hu Y, Wexler M, Wang XS#. Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity. Oncotarget. 2018 10;9(53):30115-30127. Read More.

2.       Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, Schiff R, Wang XS#, Li K#. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer. Oncogene. 2016 10.1038 /onc.2016.433. Read More.

Publications

  • Zhang H, Lee S, Muthakana R, Lu B, Boone DN, Lee D, Wang XS#
    Associations of intragenic rearrangement burden with immune cell infiltration and response to immune checkpoint blockade in cancer.
    Cancer Immunology Research.     2024. Feb. OF0-9.
  • Wang Y, Gao B, Zhang L, Koh SB, Zhu X, Lee S, Ouyang J, Zou
    L, Ellisen LW, Wang XS, Lan L. 
    Meiotic Protein SYCP2 Confers Resistance to DNA-Damaging Agents through R-Loop-MediatedDNA Repair.
    Nature Communications. 2024. In press.
  • Lee S, Deng L, Wang Y, Wang K, Sartor MA, Wang XS#
    IndepthPathway: an integrated tool for in-depth pathway enrichment analysis based on single cell sequencing data
    Bioinformatics    . 2023 Jun 1;39(6): btad325.
  • Wang XS#, Lee S, Zhang H, Tang G, Wang Y.
    An integral genomic signature approach for tailored cancer therapy using genome-wide sequencing data.
    Nature Communications.     2022 13(1):2936.
  • Loo SK, Yates ME, Yang S, Oesterreich S, Lee AV, Wang XS#. 
    Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance. 
    Genes Chromosomes Cancer    . 2022 61(5):261-273.
  • Wang X, Veeraraghavan J, Liu C, Cao X, Qin L, Kim J, Tan Y, Loo S, Hu Y, Lin , Lee S, Shea M, Mitchell T, Li S, Ellis M, Hilsenbeck SG, Schiff R, Wang XS#
    Therapeutic targeting of nemo-like kinase in primary and acquired endocrine-resistant breast cancer.
    Clinical Cancer Research. 2021 Feb 4;. doi: 10.1158/1078-0432.CCR-20-2961.
  • Liu CC*, Veeraraghavan J*, Tan Y, Kim JA, Wang X, Loo SK, Lee S, Hu Y, and Wang XS#.
    A novel neoplastic fusion transcript, RAD51AP1-DYRK4, confers sensitivity to the MEK inhibitor trametinib in aggressive breast cancers.
    Clinical Cancer Research. 2021 Feb 1;27(3):785-798. doi: 10.1158/1078-0432.CCR-20-2769.
  • Li L, Lin L, Veeraraghavan J, Hu Y, Wang X, Lee S, Tan Y, Schiff R, Wang XS#.
    Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
    Breast Cancer Research    . (2020) 22:84. https://doi.org/10.1186/s13058-020-01325-3
  • Liang Y, Yu L, Zhang D, Zhao X, Gao H, Slagle BL, Goss JA, Wang XS, Li K, Lin SY.
    BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K.
    Am J Cancer Res    . 2020;10(6):1900-1918.
  • Lee S*, Hu Y*, Loo SK, Tan Y, Bhargava R, Lewis MT, Wang XS#.
    Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
    Proc Natl Acad Sci U S A.    2020 Apr 22:201921333. doi: 10.1073/pnas.1921333117.
  • Xu Chi, Maureen A. Sartor, Sanghoon Lee, Meenakshi Anurag, Snehal Patil, Pelle Hall, Matthew Wexler, Xiaosong Wang#.
    Universal Concept Signature Analysis: Genome-Wide Quantification of New Biological and Pathological Functions of Genes and Pathways.
    Briefings in Bioinformatics    , 2019 Oct. https://doi.org/10.1093/bib/bbz093.
  • Wang X, Tan Y, Cao X, Kim JA, Chen T, Hu Y, Wexler M, Wang XS#.
    Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity.
    Oncotarget    . 2018 10;9(53):30115-30127.
  • Panebianco F, Kelly LM, Liu P, Zhong S, Dacic S, Wang XS, Singhi AD, Dhir R, Chiosea SI, Kuan SF, Bhargava R, Dabbs D, Trivedi S, Gandhi M, Diaz R, Wald AI, Carty SE, Ferris RL, Lee AV, Nikiforova MN, Nikiforov YE.
    THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.
    Proc Natl Acad Sci U S A.     10.1073/pnas.1614265114.
  • Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, Schiff R, Wang XS#, Li K#.
    Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.
    Oncogene     2016 1038/onc.2016.433.
  • Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R. and Wang XS#.
    Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers.
    Nature Communications.     2016 Oct 3;7:12991.
  • Kim JA, Anurag M, Veeraraghavan J, Schiff R, Li K, Wang XS#.
    Amplification of TLK2 Induces Genomic Instability via Impairing the G2/M Checkpoint.
    Mol Cancer Res.     2016 Aug 3. pii: molcanres.0161.2016.
  • Veeraraghavan J, Ma J, Hu Y, Wang XS#.
    Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.
    Breast Cancer Res Treat. 2016 Jul;158(2):219-32.
  • Qin L, Xu Y, Xu YX, Ma G, Liao L, Wu YL, Li Y, Wang X, Wang XS, Jiang J, Wang J, and Xu JM.
    NCOA1 Promotes Angiogenesis in Breast Tumors by Simultaneously Enhancing both HIF1α- and AP-1-mediated VEGFa Transcription.
    Oncotarget     2015 6:23890-904.
  • Song XZ, Zhang CW, Zhao MK, Chen H, Liu X, Chen JW, Lonard DM, Qin L, Xu JM, Wang XS, Li F, O’Malley BW, Wang J.
    Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.
    PLOS ONE.    2015 DOI: 10.1371/journal.pone.0140011.
  • Veeraraghavan J*, Tan Y*, Cao XX*, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJN, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS#.
    Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers. 
    Nature Communications.    2014 5:4577. doi: 10.1038/ncomms5577.
  • Fan Y*, Ge N*, Wang XS*, Sun W*, Mao R, Bu W, Creighton CJ, Zheng P, Vasudevan S, An L, Yang J, Zhao YJ, Zhang H, Li XN, Rao PH, Leung E, Lu YJ, Gray JW, Schiff R, Hilsenbeck SG, Osborne CK, Yang J, Zhang H.
    Amplification and overexpression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. 
    The Journal of Pathology 2014 232:75-86.
  • Yang Y, Zhao W, Xu QW, Wang XS, Zhang Y, Zhang J.
    IQGAP3 Promotes EGFR-ERK Signaling and the Growth and Metastasis of Lung Cancer Cells. 
    PLOS One    . 2014 9:e97578.
  • Yin B, Zeng Y, Wang XS, Liu G, Zhang M, Song Y.
    Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.
    Int J Clin Exp Pathol    . 2014 7:4112-9.
  • Xu QW, Zhang Y, Wang XS#.
    [Author’s View] HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens.
    Oncoimmunology. 2013 3:e23249
  • Xu QW, Zhao W, Wang Y, Sartor MA, Han DM, Deng JX, Ponnala R, Yang JY, Zhang QY, Liao GQ, Qu YM, Li L, Liu FF, Zhao HM, Yin YH, Chen WF, Zhang Y#, Wang XS#.
    An integrated genome-wide approach to discover tumor specific antigens as potential immunological and clinical targets in cancer.
    Cancer Research    . 2012 72:6351-61
  • Yin B, Liu G, Wang XS, Zhang H, Song YS, Wu B.
    Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder. 
    Urologic Oncology.    2012 30:886-92
  • Wang XS*, Shankar S*, Dhanasekaran SM*, Ateeq B, Sasaki AT, Jing X, Robinson D, Cao Q, Prensner JR, Yocum AK, Wang R, Fries DF, Han B, Asangani IA, Cao X, Li Y, Omenn GS, Pflueger D, Gopalan A, Reuter VE, Kahoud ER, Cantley LC, Rubin MA, Palanisamy N, Varambally S, Chinnaiyan AM.
    Characterization of KRAS Rearrangements in Metastatic Prostate Cancer.
    Cancer Discovery.     2011 1:35-43.
  • Lai YQ, Ye JX, Chen J, Zhang LB, Wasi LJ, He ZS, Zhou LQ, Li H, Yan QX, Gui YT, Cai ZM, Wang XS#, Guan ZC#.
    UPK3A: A Promising Novel Urinary Marker for the Detection of Bladder Cancer.
    Urology    . 2010 76:514
  • Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM.
    An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer.
    Nature Biotechnology    . 2009 27:1005-1011
  • Varambally S, Cao Q, Mani RS, Shankar S, Wang XS,Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM.  
    Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
    Science    . 2008 5908:1695-9
  • Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang XS,Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM.
    A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. 
    Cancer Research    . 2008 68:7629-37
  • Wang XS*, Zhang Z*, Wang HC, Cai JL, Xu QW, Li MQ, Chen YC, Qian XP, Lu TJ, Yu LZ, Zhang Y, Xin DQ, Na YQ, Chen WF.
    Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma.     
    Clinical Cancer Research. 2006 12:4851-8
  • Wang XS*, Zhao H*, Xu Q, Jin W, Liu C, Zhang H, Huang Z, Zhang X, Zhang Y, Xin D, Simpson AJ, Old LJ, Na Y, Zhao Y, Chen W.
    HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma. 
    Nucleic Acids Research    . 2006 34:D607-12
  • Du P, Yu LZ, Ma M, Geng L, Wang XS, Xin DQ, Na YQ.
    Expression of SSX2 gene in human urologic neoplasms.
    Chinese journal of surgery.2005 15;43(6):379-81
  • Wang XS, Ge CL, Guo RX, Guo KJ, He SG.
    Clinical classification and timing of surgery for gallstone acute pancreatitis. 
    Chinese Journal of General Surgery. 2002 11:131-134
  • Wang XS, Zhang DX, Wang Y, Su D, Ge C, Guo R, Ito H.
    Gallstone acute pancreatitis: diagnosis and treatment. 
    Journal of abdominal emergency medicine    . 2002 22:491-498 (Japanese).